RSS-Feed abonnieren

DOI: 10.1055/s-0043-1773806
Analysis of Treatment Outcome in Large Granular Lymphocytic Leukemia: A Retrospective Study from India
Funding None.

Abstract


Large granular lymphocytic (LGL) leukemia is a rare and indolent lymphoproliferative disorder that belongs to mature T and natural killer (NK) cell neoplasms, as per the World Health Organization classification. This article assesses the response to immunosuppressive therapy. In this retrospective study, various cases of chronic lymphoproliferative disorders (CLPDs) evaluated and treated in two tertiary care settings were screened and taken for subanalyses. After fulfilling the criteria for LGL leukemia, cases were further assessed for presenting features and response to treatment. Statistical analysis was performed using the Statistical Package for the Social Sciences, version 23. Out of 384 cases of CLPDs analyzed, 14 cases of LGL leukemia were identified (3.64%) and subjected to further analysis. There were six males (42.85%) and eight females (57.14%) (M: F = 1:1.33) with an age group ranging from 42 to 82 years. Thirteen cases (92.85%) were T-LGL type, and one case belonged to NK-LGL type (7.14%). Anemia was the most common presentation (92.85% of cases), followed by lymphocytosis (85.71% of cases) and neutropenia (78.57% of cases). Four patients (28.57%) presented with thrombocytopenia, and two patients presented with pancytopenia (14.28%). Splenomegaly was seen in two patients (14.28%), and lymphadenopathy in one patient (7.14%). One patient (7.14%) had rheumatoid arthritis, and one (7.14%) had recurrent chest infections. Out of the 14 cases, 5 (35.71%) attained complete remission, 5 (35.71%) attained partial remission, 2 patients were resistant to first-line treatment, and 2 patients were closely followed with observation only. The overall treatment response rate was 83.33%. This study highlights the excellent response rates with immunosuppressive therapy in a rare lymphoproliferative disorder.
Publikationsverlauf
Artikel online veröffentlicht:
13. Oktober 2023
© 2023. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Swerdlow SH, Campo E, Pileri SA. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127 (20) 2375-2390
- 2 Imamura N, Kuramoto A. Effect of splenectomy in aggressive large granular lymphocyte leukaemia. Br J Haematol 1988; 69 (04) 577-578
- 3 Cheon H, Dziewulska KH, Moosic KB. et al. Advances in the diagnosis and treatment of large granular lymphocytic leukemia. Curr Hematol Malig Rep 2020; 15 (02) 103-112
- 4 Suzuki R, Suzumiya J, Nakamura S. et al; NK-cell Tumor Study Group. Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia 2004; 18 (04) 763-770
- 5 Shah MV, Hook CC, Call TG, Go RS. A population-based study of large granular lymphocyte leukemia. Blood Cancer J 2016; 6 (08) e455
- 6 Bareau B, Rey J, Hamidou M. et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica 2010; 95 (09) 1534-1541
- 7 Mohan SR, Maciejewski JP. Diagnosis and therapy of neutropenia in large granular lymphocyte leukemia. Curr Opin Hematol 2009; 16 (01) 27-34
- 8 Lamy T, Moignet A, Loughran Jr TP. LGL leukemia: from pathogenesis to treatment. Blood 2017; 129 (09) 1082-1094
- 9 Semenzato G, Zambello R, Starkebaum G, Oshimi K, Loughran Jr TP. The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis. Blood 1997; 89 (01) 256-260
- 10 O'Keefe CL, Plasilova M, Wlodarski M. et al. Molecular analysis of TCR clonotypes in LGL: a clonal model for polyclonal responses. J Immunol 2004; 172 (03) 1960-1969
- 11 Epling-Burnette PK, Sokol L, Chen X. et al. Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling. Blood 2008; 112 (12) 4694-4698
- 12 Chang H, Kamel-Reid S, Hussain N, Lipton J, Messner HA. T-cell large granular lymphocytic leukemia of donor origin occurring after allogeneic bone marrow transplantation for B-cell lymphoproliferative disorders. Am J Clin Pathol 2005; 123 (02) 196-199
- 13 Moignet A, Lamy T. Latest advances in the diagnosis and treatment of large granular lymphocytic leukemia. Am Soc Clin Oncol Educ Book 2018; 38: 616-625
- 14 Sanikommu SR, Clemente MJ, Chomczynski P. et al. Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL). Leuk Lymphoma 2018; 59 (02) 416-422
- 15 Loughran Jr TP, Zickl L, Olson TL. et al. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia 2015; 29 (04) 886-894
- 16 Moignet A, Hasanali Z, Zambello R. et al. Cyclophosphamide as a first-line therapy in LGL leukemia. Leukemia 2014; 28 (05) 1134-1136
- 17 Poullot E, Zambello R, Leblanc F. et al. Chronic natural killer lymphoproliferative disorders: characteristics of an international cohort of 70 patients. Ann Oncol 2014; 25 (10) 2030-2035